Gastroenterology Report 81 2020 1124 doi 101093gastrogoz061 Advance Access Publication Date 25 November 2019 Review R E V I E W Immunotherapy immune checkpoint inhibitors colorectal cancer future deficient mismatchrepair tumours Nicolas Huyghe1 Pame la Baldin2 Marc Van den Eynde13 1Institut Recherche Clinique et Expe rimentale Pole MIRO UCLouvain Brussels Belgium 2Department Pathology Cliniques Universitaires StLuc Institut Roi Albert II Brussels Belgium 3Department Medical Oncology Cliniques Universitaires StLuc Institut Roi Albert II Brussels Belgium Corresponding author Service dOncologie Me dicale Institut Roi Albert II Cliniques Universitaires SaintLuc Institut Recherche Clinique et Expe rimentale Universite catholique Louvain UCLouvain Avenue Hippocrate 10 1200 Brussels Belgium Tel þ3227641041 Fax þ3227645428 Email marcvandeneyndeuclouvainbe Abstract Following initial success melanoma lung tumours immune checkpoint inhibitors ICIs recognized major immunotherapy treatment modality multiple types solid cancers In colorectal cancer CRC small subset mismatchrepairdeﬁcient microsatelliteinstabilityhigh dMMRMSIH derive beneﬁt immunotherapy vast majority patients proﬁcient MMR pMMR microsatellite stable MSS CRC Immunoscore consensus molecular subtype classiﬁcations promising biomarkers predicting therapeutic efﬁcacy selected CRC In pMRRMSS CRC biomarkers needed understand molecular mechanisms governing immune reactivity predict relationship treatment The continuous development bio markers offer new perspectives personalized treatments targeting oncological options including ICIs modify tumourimmune microenvironment In review focus CRC discuss current status ICIs role biomarkers predict response immunotherapy approaches explored render pMMRMSS CRC immunogenic use combined therapies Key words colorectal cancer immunotherapy immune checkpoint inhibitors immune response immunoscore Introduction Colorectal cancer CRC second common cancer women common men Despite advances diagnosis management disease CRC remains fifth cause cancerrelated death women fourth cause men 1 Moreover global CRC burden expected increase 60 2030 2 The immune distinguishes self nonself binding Tcell receptors TCR Tcells complexes peptides major histocompatibility complex MHC class I molecules presented surface cells cluding tumour cells 3 4 Recognition peptideMHC class I complexes TCR insufficient Tcell activation TCRMHC signalling pathways modulated costimulatory Submitted 7 August 2019 Revised 25 September 2019 Accepted 22 October 2019 VC The Authors 2019 Published Oxford University Press Sixth Afﬁliated Hospital Sun Yatsen University This Open Access article distributed terms Creative Commons Attribution NonCommercial License httpcreativecommonsorg licensesbync40 permits noncommercial reuse distribution reproduction medium provided original work properly cited For commercial reuse contact journalspermissionsoupcom 11 12 N Huyghe et al coinhibitory signals tumour cells exploit escape destruction 5 6 Immune checkpoint inhibitors ICIs type immunotherapy antibodies ICIs target coinhibitory receptors cytotoxic Tlymphocyteassociated antigen 4 CTLA4 programmed cell death protein 1 PD1 Tcells immunecell subpopulations ligands programmed cell death protein 1 ligand 1 PDL1 tu mour cells immune cells Over past decade ICIs revolutionized field oncology demonstrated clinical efficacy cancers including melanoma non smallcell lung cancer To date inhibitory receptors lymphocyteactivation gene 3 LAG3 Tcell immunoglobulin Ig mucin 3 TIM3 Tcell immunoreceptor Ig ITIM domains TIGIT activating receptors tumour necrosis factor receptor TNFR superfamily member 4 OX40 glucocorticoid induced TNFRrelated protein inductible Tcell costimulator CD40 identified currently evaluated targets monoclonal antibodies different clinical trials 7 In CRC shown patients subset mismatchrepairdeficient microsatellite instabilityhigh dMMRMSIH tumours likely respond treatment ICIs 810 This subset characterized increased number tumour mutations 11 inactivation mismatchrepair MMR genes MSH2 MLH1 MSH6 PMS2 1215 In 12 CRC cases epigenetic changes cause sporadic dMMRMSIH particular methylation MLH1 promoter While 3 CRC cases dMMRMSIH germline MMR mutation Lynch syndrome 16 In 2017 Food Drug Administration FDA approved antiPD1 inhibitors pembrolizumab KeytrudaVR Merck nivolumab OpdivoVR BristolMyers Squibb treatment patients dMMR MSIH CRC European Medicines Agency waiting results phase III randomizedcontrolled studies Unlike dMMRMSIH CRC patients ICIs provide limited clinical benefit CRC patients proficient MMR mi crosatellite stable pMMRMSS tumours 8 For patients ICIs actively explored combination treatments aim increase intratumoural immune response render tumour immunereactive In review discuss current use ICIs CRC role biomarkers predict CRC response immunotherapy approaches currently der investigation render pMMRMSS CRC immunogenic use combined therapies Immunotherapy CRC current status Ipilimumab YervoyVR BristolMyers Squibb monoclonal tibody targets CTLA4 protein receptor activate immune 1721 Its rapid success monoclo nal antibodies PD1 ligand PDL1 2225 led active investigation ICIs cancer types In initial trials included patients unselected metastatic CRC mCRC 100 patients treatmentrefrac tory mCRC experienced partial complete response following antiCTLA4 2628 Retrospectively responders harboured dMMRMSIH tumours Most tumours foster immu nogenic microenvironment characterized high overall mu tation burden 12 mutations 106 DNA bases associated tumour neoantigens T helper 1 Th1 cytotoxic immune response upregulation PD1PDL1positive cells 2933 Based observed impressive tumour response enthusiasm immunotherapy CRC grew studies investigated therapeutic potential PD1 inhibitors antiPD1PDL1 treatment 23 Le colleagues reported results phase II proofof concept study KEYNOTE016 dMMRMSIH tumours treated pembrolizumab 10 mgkg 2 weeks 8 In trial included 41 patients dMMRMSIH pMMRMSS chemorefractory mCRC dMMRMSIhigh nonCRC patients overall response rate ORR 40 4 10 patients Clinically durable responses observed patients dMMRMSIH mCRC response ORR ¼ 0 ob served pMMRMSS mCRC 018 Treatment tolerated overall 17 41 patients experienced grade 34 treatmentrelated adverse event TRAE The updated results trial included 86 dMMRMSIH cancers confirmed ORR 53 21 complete responses In CRC objective responses observed 52 patients 34 The 2year overall survival OS rate 64 highly pre treated cancers 34 CheckMate142 multicohort nonrandomized phase II study evaluated efficacy safety nivolumab 3 mgkg 2 weeks combination ipilimumab 1 mgkg 3 6 weeks nivolumab single agent previously treated treatmentnaıve dMMRMSIH mCRC 9 10 35 The results study confirmed impressive treatment benefit drugs setting In chemorefractory mCRC patients ORR nivolumab monotherapy n ¼ 74 31 nivolumabipilimumab combination n ¼ 119 55 1year OS rates 734 85 respectively 9 10 In treatment naıve patients corresponding ORR 1year OS rates firstline patients treated combination regimen n ¼ 45 60 83 respectively 10 With 2 years followup time reporting median OS cohorts reached Grade 34 TRAEs higher combination regimen 32 cohort received combined therapy lowdose ipilimumab 1 mgkg 6 weeks In patients grade 34 TRAEs 16 suggesting lowdose combination best treatment regimen set ting Efficacy nivolumab ipilimumab combination recently reported preoperative setting In ongo ing study authors preliminarily reported short preopera tive treatment 6 weeks ipilimumab 1 mgkg day 1 plus nivolumab 3 mgkg day 1 15 nonmetastatic colon cancer safe led major pathological response cid22 resid ual vital tumour cells dMMRMSIH tumours seven seven patients 36 No sign pathological response 85100 residual vital tumour cells observed patients pMMRMSS CRC tumours Several randomized phase III trials currently ongoing dMMRMSIH mCRC evaluate efficacy antiPD1 anti PDL1 antiCTLA4 combined compared chemotherapy targeted therapy 37 However dMMRMSIH status recognized favourable prognosis localized CRC 38 results lower proportion patients 34 metastatic dMMRMSIH CRC 39 available benefit trials Unlike patients dMMRMSIH mCRC immunotherapy demonstrated clinical benefit pMMRMSS mCRC subset constitutes tumours In pivotal KEYNOTE016 study pembrolizumab responses observed patients 8 consistently lack effi cacy immunotherapy early studies nonselected patients pMMRMSS mCRC In CheckMate142 study limited responses seen pMMR MSS tumours The lack CRC immunoreactivity recruit ment immune cells fundamental obstacle efficacy Combination treatment PD1 inhibitors The future immunotherapy pMMRMSS CRC 13 modulators immune checkpoint molecules CTLA4 beneficial subset patients pMMR MSS tumours reported recent study 40 Nevertheless alternative approaches modulate tumourimmune micro environment currently explored CRC patients harbour pMMRMSS subtype Biomarkers response immunotherapy dMMRMSI status The presence dMMRMSIH solid tumours including CRC clear potential biomarker response immunother apy 7 However given complexity antitumour im mune response intratumoural intermetastasis heterogeneity dMMR status presumably accurately identify responders ICIs 41 Identification precise reliable predictive biomarkers continues unmet clinical need A summary promising biomarkers discussed shown Figure 1 PD1PDL1 expression PD1 expressed activated Tcells Bcells natural killer NK cells bind ligand PDL1 expressed tumour cells 42 This expression induced interferongamma IFNc produced activated lympho cytes PDL1 expression measured immunohistochemical staining extensively evaluated predictive bio marker response ICIs Interestingly tumour types nonsmallcell lung carcinoma NSCLC gastric cancer oesophageal tumours PDL1 expression useful predictive marker response antiPD1 therapy 4346 However issues prevent PDL1 expression clinically useful biomarker The use PDL1detection antibodies lack standardization PDL1expression evaluation percentage positive cells cutoff ranging 1 50 tumour cells stained limit statistical significance Moreover PDL1 expression induced IFNc constitutive oncogene activation 47 PDL1 expression dynamic process changes according tumour mi croenvironment disease stage influ enced treatment 48 PDL1 expression tumours uniform sampling time location affect results PDL1 staining 49 Finally patients respond ICIs express PDL1 limit clinical impact In CRC PDL1 expression poorly correlated dMMR MSIH status 50 associated response Figure 1 Schematic representation colorectalcancerimmune subgroups linked biomarkers potential treatment strategies Immunocompetent tumour green circle characterized coordinated immune response high Tcells CD3 CD8 Th1 macrophage inﬁltration upregulation immune checkpoint molecules CTLA4 PD1 PDL1 Immune evasion group blue circle characterized poor immune cell inﬁltration Immunosuppressed group red circle characterized high immune cell inﬁltration high inﬁltration suppressor cells suppressive cytokine release The immune evasion immu nosuppressed groups treated radiotherapy chemotherapy targeted therapy cytokine modulation approaches COX inhibition A2AR inhibition render tumours immunogenic beneﬁt ICIs Possible biomarkers response ICIs marked 1 6 1 PD1PDL1 ex pression 2 Tumourmutation burden 3 Mutationassociated neoantigens presentation HLA class I 4 High cytotoxic immune cells inﬁltration immunoscore 5 Geneexpression signature including CMS classiﬁcation 6 Gut microbiome A2AR adenosine A2A receptor COX cyclooxygenase2 CTLA4 cytotoxic Tlympho cyteassociated protein 4 HLA human leucocyte antigens IFNc interferongamma IL17 interleukin 17 MDSC myeloidderived suppressorderived cells PD1 pro grammed death protein 1 PDL1 programmed deathligand 1 TCR Tcell receptor TGFb transforming growth factorbeta Th17 T helper 17 CMS consensus molecular subtype 14 N Huyghe et al survival registration studies 35 limiting impact particular type solid tumour A recent meta analysis revealed PDL1 expression serve signifi biomarker negative prognosis related clinicopathological characteristics 51 Endogenous antitumour Tcell immunity largely restricted PD1high cytotoxic lymphocytes Infiltration NSCLC PD1 high CD8þ Tcells recently associated clinical response antiPD1 52 53 Interestingly Llosa colleagues similarly reported pMMRMSS tumours infil trated PD1high CD8þ cytotoxic lymphocytes sup pressor T helper 17 Th17 cells expressing high level PDL1 immune microenvironment resembling dMMRMSIH associated pembrolizumab benefit 54 As previously reported digestive cancers melanoma 52 PD1high CD8þ cytotoxic lymphocytes characterized exhaustedmemory transcriptome suggesting presence antitumour Tcell repertoire 54 Neoantigens mutational burden Due hypermethylation MLH1 55 56 mutations MMR genes 57 dMMRMSIH tumours harbour high fre quency insertionsdeletions indels microsatellite sequen ces 58 high tumour mutational burden TMB 59 result high mutationassociated neoantigen MANA load 2931 These neoantigens processed presented dendritic cells leading priming coordinated adaptive anticancer immune response 32 explains higher density tumourinfiltrating lymphocytes TILs activated Th1 cells increased type I interferon production ob served tumours This tumourimmune surveillance leads immunoediting concept Three essential phases proposed elimination equilibrium escape 60 During elimination innate adaptive coordinate im mune responses act successful eradication tumour cells During equilibrium phase continuous im muneselection pressure induces Darwinian selection process new tumour variants emerge carrying genetic epigenetic changes tumour behaviour upregulation checkpoint receptors including CTLA4 PD 1 PDL1 indolamine 2 3dioxygenase 1 IDO1 LAG3 33 downregulation antigenpresenting molecules During escape phase tumourderived soluble factors tribute induction local immunosuppressive environ ment favouring immune escape progression metastasis 61 62 In CRC 128 tumours simultaneously present TMBhigh dMMRMSIH PDL1 expression 50 A high percentage concordance 442 TMBhigh dMMRMSIH ob served 50 predictive response ICIs 40 63 However PDL1 expression demonstrates great variability expressed dMMRMSIHnegative andor TMB low cases Interestingly possible TMBhigh absence dMMRMSIH dMMRMSIH TMBlow rare 50 There need standardize PD1PDL1 expres sion define cutoffs TMB interpretation The develop ment liquidbiopsy method identify tumours dMMRMSIH TMBhigh noninvasive technique demon strating efficacy determination response ICIs 64 Additionally tumours harbouring mutations region encoding POLE exonuclease domain presented high TMB MANA load 65 66 POLE mutations present 12 CRC tumours Similarly dMMRMSIH CRC patients POLEmutated CRC good prognosis result ing lower proportion mCRC stage IIII CRC 67 They present higher level CD8þ lymphocyte infiltra tion expression cytotoxic Tcell markers effector cyto kines 68 Given similarly enhanced immunogenicity POLEmutated CRCs dMMRMSIH CRCs therapeutic po tential immune checkpoint blockade subset POLE mutated CRCs particular 69 Further investigation currently underway clinical trials Therefore high TMB MANA load associated high Tlymphocyte infiltra tion Tcell diversity 7072 emerged biomarkers response ICIs tumour types 73 74 Immune infiltration immunoscore Interestingly high TMB necessary drive immune response Evaluation presence tumourinfiltrating CD3þ CD8þ lymphocytes signment immunoscore based density lo cation subsets Tcells prognostic clinical outcome patients stage IIII CRC performed better MSI MMR status 7577 The immunoscore simple scoring based numeration lymphocyte popula tions CD3CD45RO CD3CD8 CD8CD45RO core tumour invasive margin tumours The immunoscore provides score ranging Immunoscore 0 I0 low densities cell types regions Immunoscore 4 I4 high densities regions 78 13 countries 14 centres independent Recently prognostic impact immunoscore validated study samples 2681 stage IIII colon cancer patients 77 Interestingly authors showed patients high immunoscore similar tumour relapse survival dMMRMSIH status Therefore possible conclude favourable progno sis observed dMMRMSIHlocalized CRC essentially related high immune infiltration Furthermore prognostic value immunoscore validated metaanalysis studies published 2011 2018 79 supporting idea TILs play important role disease control disease stages preventing dissemination metastasis lymph nodes organs In mCRC characterized multiple tumour lesions different organs picture complex We previously reported comprehensive analysis patients having gone complete resection metastases revealed heterogeneity metastatic disease clinical impact 8083 Complex tumourimmune interrelations shape met astatic landscape terms lesion size number mutational pattern terms immunecell infiltration We observed heterogeneous immune infiltrate immunoscore mutational diversity multiple resected synchronous metachronous metastases patients Adaptive immune cells immunoscore quantified leastinfiltrated metastasis patient sociated patient longterm survival Within specific patient high immune infiltratehigh immunoscore correlated fewer metastases improved longterm survival 80 81 In patients unresectable mCRC adequate immunoscore assessment impossible reported single biopsy metastasis able accurately identify lowinfiltrated metastases overall intrametastatic immune infiltrate better estimated multiple biop sies sampling larger tumour areas 81 Importantly biopsies performance immunoscore superior PDL1 estimating reality concordance metastatic slide 80 81 This illustrated fact PD L1 stainings heterogeneous given metastasis High immunoscores reported pMMRMSS CRCs raise question immunophenotyping predict patients benefit immunotherapy Just recently authors reported higher CD3þ CD8þ Tcell densities PDL1 expression cancer cells associated higher ORR duration disease control small sub group patients dMMRMSIH mCRC treated pem brolizumab 84 This suggests lower immunoscore associated immunotherapy resistance dMMRMSIH tumours consistent reported finding lower immunoscores associated worse survival patients dMMRMSIH stage III colon cancers receiving cy totoxic chemotherapy 85 Hence combining immunogenic features tumour microenvironment TMB precise predicting immunotherapy response ei ther feature Further validation immunophenotyping predictive biomarker immunotherapy response specifi cally metastatic disease needed broad clinical utility currently explored trials NCT03608046 NCT03127007 Geneexpression signature A comprehensive reevaluation comparison CRC molecu lar geneexpression profiles enabled CRC Subtyping Consortium CRCSC identify robust consensus molecu lar subtype CMS classifications The type CMS1 immune mainly composed dMMRMSIH tumours characterized high TMB high immune infiltration acti vation BRAF mutations The second type CMS2canonical characterized WNT MYC activation The CMS3metabolic characterized cancercell metabolic regulation KRAS mutation The fourth type CMS4mesen chymal characterized stromal infiltration transforming growth factorbeta TGFb activation angiogenesis 65 Interestingly immune microenvironment CMS type different Stageindependent prognostic values signifi associations clinical biological treatment features demonstrated recently validated phase III clinical studies 8688 CMS1 CMS4 hot tumours considered immunereactive highly infiltrated immune cells opposed CMS2 CMS3 cold tumours Despite CMS1 CMS4 immunereactive pre sent distinct immune features escape mechanisms CMS1 present CD8þ Tcells CD68þ macrophage infiltration frequent upregulation immune checkpoint molecules CTLA4 PD1 PDL1 responsible main immune escape mechanism tumours 89 CMS4 present differ ent pattern immune infiltration mainly suppressive infiltration myeloidderived suppressor cells MDSCs Tregulatory cells Tregs monocytederived cells Th17 cells In tumours immunosuppressive factors TGFb CXCL12 upregulated chemokines interleukin 23 IL23 interleukin 17 IL17 90 CMS1 CMS4 tumours likely respond immune therapies treated distinctly Patients harbouring CMS1 tumours theoretically benefit The future immunotherapy pMMRMSS CRC 15 ICIs CMS4 subtype best suited strategies combining TGFb inhibitors Tregs MDSCs inhibition ICIs The CMS classification promis ing new biomarker response immune therapies case biomarkers care taken selecting biopsies resection specimens CMS classifica tion It borne mind CMS classification mainly derived samples primary nonmetastatic CRC 92 samples totally reproducible meta static samples liver metastases 91 validated metastatic setting 86 Additionally spatial temporaltu mour heterogeneity predominant metastatic setting misevaluate CMS status Thus source sample prior treatments collection carefully considered A recent study described innate immune response CRC upregulation PDL1 IDO1 linked DNA damage In order identify subtype tumours defective DNAdamage response DDR authors developed 44gene signature assay reported 80 dMMRMSIH 25 pMMRMSS tumours presented signature The DDR assay enable identi fication dMMRMSIH tumours rare cases pMMRMSS tumours likely respond ICIs 92 Microbiota The gut microbiome influences outcome cancer ther apy modulating host inflammatory response 93 94 An intact microbiome required successful tumour control response genotoxic oxaliplatin CRC immu nomodulatory therapies cyclophosphamide Recent stud ies reported important role gut microbiome ICI treatment 9597 It primary resistance ICIs melanoma lung cancers attributed abnormal gut microbiome use antibiotics One study raises hypothesis transplanting faecal material responding patients nonresponders lead im proved tumour control In study shown germfree mice transplanted faecal material melanoma patients experienced improved tumour trol augmented Tcell responses greater efficacy anti PDLI therapy 98 Metagenomics patient stool samples diagnosis revealed correlations clinical responses ICIs relative abundance Akkermansia muciniphila 95 This influence microbiome come cancer treatment function anticancer immu nity poses new questions preclinical clinical standpoint CRC field Despite evidence association gut microbiome CRC role treatment advanced metastatic CRC remains largely unexplored Immunotherapy pMMRMSS CRC strategies development The recent success antiPD1 antiCTLA4 treatments dMMRMSIH patients preclinical data showing dMMR MSIH tumours subgroup CRC theoretically benefit ICIs led design new clinical studies These trials aim select subset CRC patients likely respond ICIs design novel thera peutic strategies render tumours immunecompetent Figure 1 Some oncological treatments able cause immunogenic cell death ICDa form cell apoptosis 16 N Huyghe et al induce antitumour immune response poten tially overcome primary resistance pMMRMSS CRC ICIs The main treatment strategies currently investigated clinical trials summarized section Table 1 Radiation therapy Preclinical early clinical studies suggested radia tion therapy RT chemoradiation therapy CRT clever way expose neoantigens By damaging DNA radiother apy induces tumourcell death This releases neoantigens creat ing immunemediated antitumour responses 99 ICD 100 101 In patients neoantigens release act situ radiationinduced vaccine 102 103 This immune effect applicable irradiated tumour site dis tant sites abscopal effect 104 theoretically enhanced ICIs It shown example antiCTLA4 andor antiPDL1 combination RT work synergistically significantly improve treatment sponse including metastatic lesions outside radiation field patient outcomes metastatic melanoma NSCLC 104 105 The data understand role RT ICIs CRC limited In mCRC stereotactic body radiation therapy SBRT directed site liver metastasis combination PD1 inhibitor illicit response 106 In trial mCRC evaluating pembrolizumab palliative RT local ablation major response 111 patients ORR ¼ 9 metastatic site distant irradiated field observed RT cohort 107 Recently dual blockade CTLA4 ipilimu mab PD1 nivolumab RT 8 Gy fractions single metastatic lesion demonstrated feasibility promis ing activity phase II study included 40 patients chemorefractory mCRC 108 Among 27 patients treated protocoldefined RT 33 patients received RT progression grade 34 TRAE ORR diseasecontrol rate DCR 15 37 respectively The durability dis ease control impressive median 15 months Modification dosing schedule reduce dropout rate considered future development The outcome correlative studies biopsies wholeexome sequencing eagerly awaited Several clinical trials evaluating efficacy conventional stereotactic RT combination ICIs ongoing Table 1 Our research group currently conducting multi centre randomized phase II trial RImmune trial NCT03127007 evaluating benefit atezolizumab antiPDL1 preoperative CRT 4550 Gy 5 weeks combination 5fluorouracil locally advanced rectal cancer The trial sign delays atezolizumab administration 2 weeks CRT initiation order explore role CRT tumourimmune microenvironment The trial incorporates multiple tumour blood stool collections investigate role biomarkers previously described multiple correlative substudies Chemotherapy targeted therapies The lines treatment mCRC currently involve combination targeted therapies inhibit epidermal growth factor receptor EGFR cetuximab panitumumab angiogenesis bevacizumab aflibercept ramucirumab chemotherapy irinotecan 109113 Recent evidence suggests oxaliplatin 5fluorouracil chemotherapy regimens induce ICD releasing damage associated molecular patterns DAMPs 114 115 activating necrotic apoptotic pathways 116 The translocation calre ticulin recognized signal dendritic cells DCs mediate phagocytosis dying tumour cells Agents 5fluorouracil induce apoptosis MDSCs inhibiting immunosuppressive function increasing CD8þ Tcell function 117 The analysis immune micro environment resected CRC liver metastases revealed patients treated preoperative chemotherapy signifi cantly higher density cytotoxic memory Tcells com pared metastases untreated patients 80 81 118 Moreover CRC liver metastases achieved pathologi cal radiological responses associated signifi cantly higher immunoscore reflecting increased adaptive immune response 81 Vascular endothelial growth factor VEGF signal protein stimulates formation blood vessels It upre gulated cancer contributes tumour angiogenesis 119 It plays role immune microenvironment upregu lating immune checkpoint molecules PD1 PDL1 CTLA4 LAG3 downregulating antigenpresentation molecules Additionally VEGF inhibits DC maturation increases function suppressor cells 120128 Studies combining anti angiogenic agents ICIs chemotherapy initially suggested potentially synergistic activity FOLFOX 129 130 randomized phase III MODUL trial failed confirm preliminary findings In trial maintenance treatment combined atezolizumabbevacizumabfluoro pyrimidine firstline induction FOLFOXbevacizumab demonstrate clinical benefit progressionfree sur vival PFS OS compared bevacizumab fluoropyrimi dine Preclinical data shown cetuximab chimeric im munoglobulin G1 IgG1 monoclonal antibody directed EGFR combined FOLFIRI combination chemotherapy regimen induce ICD induces ICD mouse model CRC cell lines 131 favour activation Tcellmediated immune response 128 Cetuximab stimulate NKmediated cellantibodydependent cellular cyto toxicity 132 We previously reported patients treated pre operatively chemotherapy cetuximab higher CD3þ cytotoxic CD8þ memory infiltration global CD45ROþ Tcells core resected CRC liver tastases higher immunerelated gene expression compared treatments 80 81 This modification tumour immune microenvironment reported group 133 observed small subgroup patients RASmutated mCRC 80 This suggests immunological effect cetuximab unlike cytotoxic activity independent RASmutation status 80 This promising treatment approach currently evaluated phase II trial combining avelu mab antiPDL1 FOLFOX cetuximab firstline RAS BRAF wildtype wt mCRC AVETUX trial The preliminary results 20 patients reported demonstrating ORR 75 DCR 95 134 Another multicentre phase II trial currently investigating question cetuximab combination avelumab rechallenge mCRC patients experienced partial complete response antiEGFR plus chemotherapy firstline treatment CAVE Colon study In way group currently vestigating efficacy avelumab combined cetuximab irinotecan AVETUXIRI mCRC patients refractory chemotherapy cohort A RASmutated trial NCT03608046 The future immunotherapy pMMRMSS CRC 17 Table 1 Selection ongoing trials investigating different treatment strategies ICIs pMMRMSS CRC Combined therapy Target Clinical compound ICI compound Trial type Radiotherapy Stereotactic body radiation Toripalimab Phase IImCRC oligometastasis Trial identifier NCT03927898 Liver radiation therapy Nivolumab Ipilimumab Phase ImCRC NCT03507699 Radiation therapy Radiochemotherapy 5FU Radiation therapy Radiation therapyOr ablation Radiation therapy Radiochemotherapy Radiochemotherapy Targeted VEGFR KIT therapies Capecitabine Standard Radio chemotherapy Cediranib CMP001 Nivolumab þ Ipilimumab Atezolizumab Durvalumab 6 Tremelimumab Durvalumab 6 Tremelimumab Durvalumab 6 Tremelimumab Nivolumab Durvalumab Phase IIpMMRMSS NCT03104439 dMMRMSI CRC Phase IIILocalized rectal NCT03127007 cancer Phase IImCRC NCT02888743 Phase IImCRC NCT03122509 Phase IImCRC pMMRMSS NCT03007407 Phase IIIRectal cancer Phase IIRectal cancer NCT02948348 NCT03102047 pMMRMSS Durvalumab Phase IIIRefractory CRC NCT02484404 EGFR Panitumumab VEGFR PDGFR FGFR EGFR Nintedanib Cetuximab Nivolumab 6 Ipilimumab Pembrolizumab Pembrolizumab Cetuximab þ Irinotecan Cetuximab þ FOLFOX Cetuximab Avelumab Avelumab Avelumab EGFR EGFR EGFR VEGFA VEGFA VEGFA VEGFA Multikinase MEK MEK MEK MEK MEK MEK MEK VEGFA Bevacizumab þ Capecitabine Bevacizumab þ FOLFOX Bevacizumab þ FOLFOX Bevacizumab þ Capecitabine Regorafenib Combimetinib Regorafenib Cobimetinib Binimetinib Binimetinibþ FOLFOX FOLFIRI Trametinib Trametinib Combimetiniband Bevacizumab Phase IIRASwildtype NCT03442569 CRC Phase IIImCRC Phase IbIIPretreated NCT02856425 NCT02713373 mCRC Phase IImCRC pMMRMSS NCT03608046 NCT03174405 Phase IIUntreated mCRC CAVE Colon Phase IIPretreated RAS wildtype mCRC Randomized phase IIRefractory CRC Phase IFirstline mCRC Phase IIIIFirstline CRC Phase IIPretreated mCRC NCT02873195 NCT03176264 NCT03414983 NCT03396926 Atezolizumab PDR001 Nivolumab Pembrolizumab PDR001 Atezolizumab Phase IbPretreated mCRC NCT03081494 NCT02788279 Phase IIImCRC Atezolizumab Nivolumab 6 Ipilimumab Pembrolizumab Nivolumab 6 Ipilimumab Durvalumab Atezolizumab Nivolumab 6 Ipilimumab NCT02291289 Phase IIFirstline mCRC Phase IIIPretreated mCRC NCT03271047 Phase IbmCRC NCT03374254 Phase IIIPretreated mCRC NCT03377361 Phase IImCRC pMMRMSS NCT03428126 NCT02876224 Phase ImCRC Phase IIRefractory CRC NCT02060188 Pembrolizumab Nivolumab Atezolizumab Avelumab Pembrolizumab Pembrolizumab refractory pMMRMSS Phase IIAdvanced cancer including CRC NCT03228667 Phase IIImCRC Phase IIImCRC Phase ImCRC NCT03168139 NCT02834052 NCT03256344 continued MEK CD38 LAG3 Cobimetinib Daratumumab anti LAG3 antibody PI3K MNK Copanlisib Nivolumab Phase IIIUnresectable mCRC pMMRMSS NCT03711058 eFT508 Avelumab Phase IIRelapsed NCT03258398 Cytokines IL15 superagonist ALT803 CXCL12 Cytokines release GMCSF Olaptesed pegol PolyICLC talimogene laherparepvec Atezolizumab 18 N Huyghe et al Table 1 continued Combined therapy Others Target CSF1R COX2 IDO1 IDO1 DNMT DNMT DNMT HDAC Clinical compound ICI compound Trial type Trial identifier Pexidartinib Celecoxib Epacadostat Epacadostat Azacitidine Azacitidine Azacitidine romidepsin Durvalumab Nivolumab 6 Ipilimumab Nivolumab Phase ICRC Phase IIStage IIII CRC NCT02777710 NCT03026140 Phase IIISolid tumours NCT02327078 cluding CRC Pembrolizumab Phase IIIRefractory CRC NCT02959437 Durvalumab Pembrolizumab NSCLC Phase IImCRC Phase IPretreated mCRC NCT02811497 NCT02512172 Thymidine phosphorylase Thymidine TAS102 TAS102Bevacizumab Nivolumab Nivolumab Phase IIRefractory CRC Phase IIPretreated mCRC NCT02860546 NCT02848443 phosphorylaseVEGFA Capecitabine Glucose metabolism Metformin Nivolumab Phase IIRefractory pMMR NCT03800602 Adenosine receptor AZD4635 Durvalumab Phase ISolid malignancies NCT02740985 MMS CRC Adenosine receptor NIR178 Adenosine receptorCD73 NIR178NZV930 PDR001 PDR001 EGFRCAR Tcells express ing antiPD1 anti CTLA4 antibodies EGFRCAR Tcells express ing antiPD1 antibodies MUC1CAR Tcells express ing antiPD1 anti CTLA4 antibodies including CRC Phase IIAdvanced solid NCT03207867 tumours including CRC Phase IAdvanced solid NCT03549000 tumours including CRC Phase IIIEGFR positive ad vanced malignant solid tumours Phase IIIEGFR positive ad vanced malignant solid tumours Phase IIIMUC1 positive advanced malignant solid tumours NCT03182816 NCT02873390 NCT03179007 Clinical trial details accessed ClinicalTrialsgov 5FU 5ﬂuorouracil Avelumab antiPDL1 Atezolizumab antiPDL1 CMP001 antiTLR9 CAR chimeric antigen receptor CRC colorectal cancer CSF1R colony stim ulating factor 1 receptor COX2 cyclooxygenase2 CXCL12 CXC motif chemokine 12 DNMT DNA methyltransferase Durvalumab antiPDL1 dMMRMSI mis matchrepairdeﬁcient microsatellite instable EGFR epidermal growth factor receptor FGFR ﬁbroblast growth factor receptor FOLFIRI 5ﬂuorouracil leucovorin irinotecan FOLFOX 5ﬂuorouracil leucovorin oxaliplatin GMCSF granulocytemacrophage colony stimulating factor HDAC histone deacetylase IDO1 indolamine 23dioxygenase 1 IL15 interleukin 15 Ipilimumab antiCTLA4 KIT tyrosine kinase Kit LAG3 lymphocyteactivation gene 3 mCRC metastatic colorec tal cancer MEK mitogenactivated protein kinase MNK mitogenactivated protein kinase interacting protein kinase MUC1 mucin1 Nivolumab antiPD1 NSCLC nonsmallcell lung cancer PDGFR plateletderived growth factor receptor PDR001 antiPD1 Pembrolizumab antiPD1 pMMRMSS mismatchrepairproﬁcient microsatellite stable Toripalimab antiPD1 Tremelimumab antiCTLA4 VEGFA vascular endothelial growth factor A VEGFR vascular endothelial growth factor receptor antiEGFR treatment cohort B RAS wt We hope confirm immunological effect cetuximab provoke tu mour response combined avelumab irrespective RAS mutation We plan prospectively investigate pre viously described efficacy biomarkers For reason multiple tumour biopsies blood collection planned correla tive substudy Preclinical studies reported MEK inhibitors associated tumour immunological effect 135 136 MEK inhibition upregulates MHC class I expression 137 pro motes antigen presentation surface tumour cells recognition CD8þ Tlymphocytes recognize kill tumour cells In mouse models combination PD1 MEK inhibitors synergistic tumourgrowth inhibition compared singleagent treatment 135 136 This efficacy clinically observed phase Ib study combining atezolizumab antiPDL1 cobimetinib antiMEK 23 chemorefractory mCRC patients ORR 17 4 23 patients 129 The IMblaze370 Cotezo randomized phase III trial failed confirm efficacy Chemorefractory mCRC patients randomized combined experimental arm cobimetinib atezolizumab experience increased tumour sponse survival benefit PFS OS compared patients treated atezolizumab regorafenib 138 The PI3KAKTmTOR pathway implicated cell survival migration proliferation dysregulated cancer 139 Interestingly recent observation suggests inhibition pathway effect tumour cells effect immune microenvironment preventing activation immunosuppressive pathway 140 The strategy combining PI3K inhibitor ICI lead increased ICI response tumours immunosuppressive environment pMMRMSS CRC Ongoing trials evaluating chemo targeted therapies summarized Table 1 Cytokines Cytokines chemokines immunesystem molecular messengers molecules Therefore targeting combination ICIs approach currently vestigation 141 Interleukin 15 IL15 glucoprotein belongs 4alphahelix bundle family cytokines In immune sys tem IL15 mainly expressed monocytes macrophages DCs characterized Tcell growth factor 142 Upon binding receptor highly expressed CD8þ NK cells IL15 promotes proliferation function cells The efficacy IL15 administration limited short halflife vivo 143 chimeric fusion protein ALT803 increases vivo halflife developed This treatment currently tested combination different ICIs patients advanced cancer including mCRC patients NCT03228667 CXCL12 chemokine mainly expressed cancer associated fibroblasts reported mediate immune exclusion mouse models 144 Therefore idea blocking CXCL12 binding receptors CXCR4 CXCR7 interesting novel approach increase efficacy ICIs immuneexcluded tumours low immunoscore This ap proach investigated study combining olaptesed NOXA12a heptamer binds CXCL12 high affinity pembrolizumab NCT03168139 Another way potentially increase efficacy stimulate cytokine release A phase III trial evaluating combi nation pembrolizumab polyICLCa molecule stim cytokine release inducing IFNc production ulates generates inflammatory response NCT02834052 Even function cancer controversial 145 human cytokine granulocytemacrophage colony stimulating factor GMCSF known regulate cell differentiation 146 local recruitment dendritic cells 147 This enhance tumour associated antigen presentation Tcells 148 activate effectors immune response including macrophages NK cells 147 149 A trial evaluating virus talimogene laherparepvec encodes immunostimulating factor GM CSF This virus infects replicates tumour cells leading cell lysis GMCSF release Combining talimogene laherparepvec virus atezolizumab promising approach increase antitumour immune response mCRC NCT03256344 Others Other trials underway aim combine ICIs molecules target metabolic pathways Two trials currently testing nivolumab ipilimumab combined cele coxib COX2 inhibitor NCT03926338 NCT03026140 The expression COX2 induce expression IDO1 150 IDO1 intracellular enzyme catalyses tryptophan kynurenine pathway 151 induces depletion tryptophan leading immunosuppressive environment 152 153 Higher IDO1 expression CRC tumours correlates progres sive disease impaired clinical outcome 154 For rea son inhibitors IDO1 epacadostat currently tested NCT02959437 combination NCT02327078 ICIs One trial assessing combination metformin nivolumab NCT03800602 based preliminary reported efficacy metastatic melanoma 155 The activation A2a A2b adenosine receptors immune cells inhibits proliferation activation result ing strong immunosuppression Tcell anergy 156 157 The future immunotherapy pMMRMSS CRC 19 Adenosine mechanisms Tregs maintain immunotolerance 158 Inhibition adenosine A2a receptor potentiate ICIs durvalu mab antiPDL1 prove worthwhile treatment approach This strategy currently evaluated safety trial patients advanced solid malignancies including CRC NCT02740985 Cibisatamab CEA CD3 TCB RG7802 RO6958688 Tcell bispecific antibody TCB simultaneously binds carcino embryonic antigen CEA tumour cells CD3 Tcells crosslinking cancer cells Tcells This leads Tcell engagement activation independently preexisting im munity Tcell infiltration tumour inflammation In ongo ing studies encouraging clinical activity reported patients metastatic pMMRMSS CRC treated CEATCB monotherapy activity enhanced combined atezolizumab 159 In combination therapy group ORR 18 n ¼ 2 observed DCR 82 Toxic effects manageable CEATCB Tcell bispecific antibody efficacy solid tumours specifically pMMRMSS CRC Finally adoptive cellbased immunotherapy genetically modified Tcells represents promising emerging modality CRC treatment Adoptive cell therapy based collection vitro expansion transfusion Tcells patients Tcells patients These Tcells engineered express chimeric antigens receptors CARs selected ability bind tumour antigens Moreover CAR Tcells engi neered recognize tumour antigens produce cytokines ICIs However despite fact CAR Tcells successfully treating haematological cers Bcell malignancies efficacy applicability cellbased immunotherapy remain proved CRC solid tumours 7 160 Nevertheless EGFRCART Mucin1 MUC1CAR Tcells expressing antiPD1 antiPD1 antiCTLA4 currently clinically tested solid tumours expressing antigens EGFR MUC1 Conclusion It undeniable considerable advances recent FDA approval ICIs treatment dMMR MSIH mCRC Unfortunately dMMRMSIH CRC represent small subgroup CRC pMMRMSS mCRC benefit ICIs Beyond dMMRMSIH tumour status continuous velopment new biomarkers immunoscore CMS classification led better understanding molecu lar mechanisms define immune reactivity CRC relationship oncological treatments This provides new perspectives enables personalized approach wards patient management continue investi gated translational aspect clinical trials That said biomarkers governed heterogeneous expression pattern time space Therefore source tumour sample treatments administered prior sample collection carefully considered The key remaining challenge identify het erogeneous spectrum mCRC patients likely benefit ICIs combination oncolog ical treatments specific genomic immune tumour characteristics This question currently investi gation ongoing clinical trials 20 N Huyghe et al Funding NH research fellow supported grant Belgian National Fund Scientific Research Te le vieFNRS 7460918F Acknowledgements The authors wish thank Aileen Eiszele English language writing assistance The Figure 1 cre ated Biorendercom Conflicts The authors conﬂicts declare References 1 Ferlay J Colombet M Soerjomataram I et al Estimating global cancer incidence mortality 2018 GLOBOCAN sources methods Int J Cancer 2019144194153 2 Arnold M Sierra MS Laversanne M et al Global patterns trends colorectal cancer incidence mortality Gut 20176668391 4 3 Khalil DN Smith EL Brentjens RJ et al The future cancer treatment immunomodulation CARs combination im munotherapy Nat Rev Clin Oncol 20161327390 Schreiber RD Old LJ Smyth MJ Cancer immunoediting inte grating immunitys roles cancer suppression promo tion Science 2011331156570 Sharma P Allison JP The future immune checkpoint ther apy Science 20153485661 5 6 Townsend SE Allison JP Tumor rejection direct costi mulation CD8þ T cells B7transfected melanoma cells Science 199325936870 7 Ganesh K Stadler ZK Cercek A et al Immunotherapy lorectal cancer rationale challenges potential Nat Rev Gastroenterol Hepatol 20191636175 Le D Uram J Wang H et al PD1 blockade tumors mismatchrepair deﬁciency N Engl J Med 2015372250920 8 9 Overman MJ McDermott R Leach JL et al Nivolumab patients metastatic DNA mismatch repairdeﬁcient microsatellite instabilityhigh colorectal cancer CheckMate 142 open label multicentre phase 2 study Lancet Oncol 201718118291 10 Overman MJ Lonardi S Wong KYM et al Durable clinical beneﬁt nivolumab plus ipilimumab DNA mismatch repairdeﬁcientmicrosatellite instabilityhigh metastatic colorectal cancer JCO 2018367739 11 Vogelstein B Papadopoulos N Velculescu VE et al Cancer genome landscapes Science 2013339154658 12 Aaltonen LA Peltomaki P Leach FS et al Clues patho 13 genesis familial colorectal cancer Science 19932608126 Jiricny J The multifaceted mismatchrepair Nat Rev Mol Cell Biol 2006733546 14 Strand M Prolla TA Liskay RM et al Destabilization tracts simple repetitive DNA yeast mutations affecting DNA mismatch repair Nature 19933652746 Ionov Y Peinado MA Malkhosyan S et al Ubiquitous matic mutations simple repeated sequences reveal new mechanism colonic carcinogenesis Nature 1993363 55861 15 16 Gupta R Sinha S Paul RN The impact microsatellite sta bility status colorectal cancer Curr Probl Cancer 201842 54859 17 Weber JS ODay S Urba W et al Phase III study ipilimu mab patients metastatic melanoma JCO 200826 59506 18 Yang JC Hughes M Kammula U et al Ipilimumab anti CTLA4 antibody causes regression metastatic renal cell cancer associated enteritis hypophysitis J Immunother 20073082530 19 Kwon ED Drake CG Scher HI et al Ipilimumab versus pla cebo radiotherapy patients metastatic castrationresistant prostate cancer progressed af ter docetaxel chemotherapy CA184043 multicentre randomised doubleblind phase 3 trial Lancet Oncol 2014 1570012 20 Carthon BC Wolchok JD Yuan J et al Preoperative CTLA4 blockade tolerability immune monitoring setting presurgical clinical trial Clin Cancer Res 201016286171 21 Hodi FS Butler M Oble DA et al Immunologic clinical effects antibody blockade cytotoxic T lymphocyte associated antigen 4 previously vaccinated cancer patients Proc Natl Acad Sci U S A 2008105300510 22 Topalian SL Sznol M McDermott DF et al Survival durable tumor remission longterm safety patients ad JCO 201432 vanced melanoma receiving nivolumab 102030 23 Brahmer JR Tykodi SS Chow LQ et al Safety activity antiPDL1 antibody patients advanced cancer N Engl J Med 2012366245565 24 Powles T Eder JP Fine GD et al MPDL3280A antiPDL1 treatment leads clinical activity metastatic bladder cancer Nature 201451555862 25 Ansell SM Lesokhin AM Borrello I et al PD1 blockade nivolumab relapsed refractory Hodgkins lymphoma N Engl J Med 20153723119 26 Chung KY Gore I Fong L et al Phase II study anti cytotoxic Tlymphocyteassociated antigen 4 monoclonal antibody tremelimumab patients refractory meta static colorectal cancer JCO 201028348590 27 ONeil BH Wallmark JM Lorente D et al Safety antitu mor activity antiPD1 antibody pembrolizumab patients advanced colorectal carcinoma PLoS One 2017 12e0189848 28 Lipson EJ Sharfman WH Drake CG et al Durable cancer gression offtreatment effective reinduction therapy antiPD1 antibody Clin Cancer Res 2013194628 29 Linnebacher M Gebert J Rudy W et al Frameshift peptide derived Tcell epitopes source novel tumorspeciﬁc antigens Int J Cancer 200193611 30 Saeterdal I Bjorheim J Lislerud K et al Frameshiftmuta tionderived peptides tumorspeciﬁc antigens inher ited spontaneous colorectal cancer Proc Natl Acad Sci U S A 2001981325560 31 Schumacher TN Schreiber RD Neoantigens cancer im munotherapy Science 20153486974 32 Chen DS Mellman I Oncology meets immunology cancerimmunity cycle Immunity 201339110 33 Llosa NJ Cruise M Tam A et al The vigorous immune micro environment microsatellite instable colon cancer bal anced multiple counterinhibitory checkpoints Cancer Discov 201554351 34 Le DT Durham JN Smith KN et al Mismatchrepair deﬁ ciency predicts response solid tumors PD1 blockade Science 201735740913 35 Andre T Overman M Lonardi S et al Analysis tumor PD L1 expression biomarkers relation clinical activity The future immunotherapy pMMRMSS CRC 21 patients pts deﬁcient DNA mismatch repair dMMRhigh microsatellite instability MSIH metastatic colorectal cancer mCRC treated nivolumab NIVO þ ipilimumab IPI CheckMate 142 ESMO abstract 484PD Ann Oncol 201728Suppl 5I63 36 Chalabi M Fanchi LF Van den Berg JG et al Neoadjuvant ipi limumab plus nivolumab early stage colon cancer ESMO abstract LBA37_PR Ann Oncol 201829mdy424 37 Ciardiello D Vitiello PP Cardone C et al Immunotherapy colorectal cancer challenges therapeutic efﬁcacy Cancer Treat Rev 2019762232 52 Gros A Robbins PF Yao X et al PD1 identiﬁes patient speciﬁc CD8þ tumorreactive repertoire inﬁltrating human tumors J Clin Invest 2014124224659 53 Thommen DS Koelzer VH Herzig P et al A transcriptionally functionally distinct PD1þ CD8þ T cell pool predictive potential nonsmallcell lung cancer treated PD1 blockade Nat Med 2018249941004 54 Llosa NJ Luber B Tam AJ et al Intratumoral adaptive immu nosuppression type 17 immunity mismatch repair proﬁcient colorectal tumors Clin Cancer Res 2019255250 10115810780432ccr190114 38 Popat S Hubner R Houlston RS Systematic review micro JCO satellite instability colorectal cancer prognosis 20052360918 55 AlDubayan SH Giannakis M Moore ND et al Inherited DNA repair defects colorectal cancer Am J Hum Genet 2018102 40114 39 Colle R Cohen R Cochereau D et al Immunotherapy patients treated cancer microsatellite instability Bull Cancer 20171044251 40 Chen EX Derek J Jonker JM et al CCTG CO26 updated analy sis impact plasmadetected microsatellite stability MSS tumor mutation burden TMB phase II trial durvalumab D plus tremelimumab T best supportive care BSC versus BSC patients pts refractory metastatic colorectal carcinoma rmCRC ASCO abstract J Clin Oncol 2019373512 41 Baretti M Le DT DNA mismatch repair cancer Pharmacol Ther 20181894562 42 Gandini S Massi D Mandala M PDL1 expression cancer patients receiving anti PD1PDL1 antibodies systematic review metaanalysis Crit Rev Oncol Hematol 2016100 8898 43 Garon EB Rizvi NA Hui R et al Pembrolizumab treat ment nonsmallcell lung cancer N Engl J Med 2015372 201828 44 Hersom M Jorgensen JT Companion complementary diagnosticsfocus PDL1 expression assays PD1PD L1 checkpoint inhibitors nonsmall cell lung cancer Ther Drug Monit 201840916 45 Shah M Adenis A Enzinger P et al Pembrolizumab versus chemotherapy secondline therapy advanced esopha geal cancer phase 3 KEYNOTE181 study ASCO abstract 4010 J Clin Oncol 2019374010 46 Tabernero J Van Cutsem E Bang YJ et al Pembrolizumab chemotherapy versus chemotherapy ad vanced gastric gastroesophageal junction GGEJ adeno carcinoma phase III KEYNOTE062 study ASCO abstract LBA4007LBA07 JCO 201937LBA4007 56 Pearlman R Frankel WL Swanson B et al Prevalence spectrum germline cancer susceptibility gene mutations patients earlyonset colorectal cancer JAMA Oncol 2017346471 57 Lorans M Dow E Macrae FA et al Update hereditary colo rectal cancer improving clinical utility multigene panel testing Clin Colorectal Cancer 201817e293305 58 Arana ME Kunkel TA Mutator phenotypes DNA rep lication inﬁdelity Semin Cancer Biol 20102030411 59 Chalmers ZR Connelly CF Fabrizio D et al Analysis 100000 human cancer genomes reveals landscape tu mor mutational burden Genome Med 2017934 60 Dunn GP Old LJ Schreiber RD The Es cancer immu noediting Annu Rev Immunol 20042232960 61 Kim R Emi M Tanabe K Cancer immunoediting im mune surveillance immune escape Immunology 2007121 114 62 Stewart TJ Abrams SI How tumours escape mass destruc tion Oncogene 2008275894903 63 Schrock AB Ouyang C Sandhu J et al Tumor mutational bur den predictive response immune checkpoint inhibi tors MSIhigh metastatic colorectal cancer Ann Oncol 2019301096103 64 Georgiadis A Durham JN Keefer LA et al Noninvasive detec tion microsatellite instability high tumor mutation burden cancer patients treated PD1 blockade Clin Cancer Res 2019 10115810780432CCR191372 65 Guinney J Dienstmann R Wang X et al The consensus molec ular subtypes colorectal cancer Nat Med 20152113506 66 The Cancer Genome Atlas Network Comprehensive molec ular characterization human colon rectal cancer Nature 20124873307 47 Patel SP Kurzrock R PDL1 expression predictive bio marker cancer immunotherapy Mol Cancer Ther 201514 84756 67 Yaeger R Chatila WK Lipsyc MD et al Clinical sequencing deﬁnes genomic landscape metastatic colorectal cer Cancer Cell 20183312536e3 48 Aguiar PN Jr Santoro IL Tadokoro H et al The role PDL1 expression predictive biomarker advanced non smallcell network metaanalysis lung Immunotherapy 2016847988 cancer 49 Wang X Teng F Kong L et al PDL1 expression human cancers association clinical outcomes Onco Targets Ther 20169502339 50 Luchini C Bibeau F Ligtenberg MJL et al ESMO recommen dations microsatellite instability testing immuno therapy cancer relationship PD1PDL1 expression tumour mutational burden systematic reviewbased approach Ann Oncol 201930123243 68 Domingo E FreemanMills L Rayner E et al Somatic POLE proofreading domain mutation immune response prognosis colorectal cancer retrospective pooled bio marker study Lancet Gastroenterol Hepatol 2016120716 69 Gong J Wang C Lee PP et al Response PD1 blockade microsatellite stable metastatic colorectal cancer harboring POLE mutation J Natl Compr Canc Netw 2017151427 70 Li B Li T Pignon JC et al Landscape tumorinﬁltrating T cell repertoire human cancers Nat Genet 20164872532 71 McGranahan N Furness AJ Rosenthal R et al Clonal neoan tigens elicit T cell immunoreactivity sensitivity im mune checkpoint blockade Science 201635114639 51 Yang L Xue R Pan C Prognostic clinicopathological value PDL1 colorectal cancer systematic review metaanalysis Onco Targets Ther 201912367182 72 Anagnostou V Smith KN Forde PM et al Evolution neoan tigen landscape immune checkpoint blockade nonsmall cell lung cancer Cancer Discov 2017726476 22 N Huyghe et al 73 Samstein RM Lee CH Shoushtari AN et al Tumor muta tional load predicts survival immunotherapy multiple cancer types Nat Genet 2019512026 91 Pitroda SP Khodarev NN Huang L et al Integrated molecular subtyping deﬁnes curable oligometastatic state colorec tal liver metastasis Nat Commun 201891793 74 Chan TA Yarchoan M Jaffee E et al Development tumor mutation burden immunotherapy biomarker utility oncology clinic Ann Oncol 2019304456 75 Galon J Costes A SanchezCabo F et al Type density lo cation immune cells human colorectal tumors pre dict clinical outcome Science 200631319604 76 Mlecnik B Bindea G Angell HK et al Integrative analyses colorectal cancer immunoscore stronger predictor patient survival microsatellite instability Immunity 201644698711 77 Pages F Mlecnik B Marliot F et al International validation consensus Immunoscore classiﬁcation colon cancer prognostic accuracy study Lancet 2018391 212839 78 Galon J Mlecnik B Bindea G et al Towards introduction Immunoscore classiﬁcation malignant tumours J Pathol 2014232199209 79 Sun G Dong X Tang X et al The prognostic value immu noscore patients colorectal cancer systematic view metaanalysis Cancer Med 201981829 80 Van den Eynde M Mlecnik B Bindea G et al The link tween multiverse immune microenvironments metastases survival colorectal cancer patients Cancer Cell 201834101226e3 81 Mlecnik B Van den Eynde M Bindea G et al Comprehensive intrametastatic immune quantiﬁcation major impact immunoscore survival J Natl Cancer Inst 201811097108 82 Angelova M Mlecnik B Vasaturo A et al Evolution metas tases space time immune selection Cell 2018 17575165e16 83 Carrasco J Gizzi M Pairet G et al Pathological responses af ter angiogenesis EGFR inhibitors metastatic colorectal cancer depend chemotherapy backbone Br J Cancer 20151131298304 84 Chakrabarti S Huebner LJ Finnes HD et al Intratumoral CD3þ CD8þ Tcell densities patients DNA mismatch repairdeﬁcient metastatic colorectal cancer ceiving programmed cell death1 blockade JCO Precis Oncol 2019373532 85 Yoon HH Shi Q Heying EN et al Intertumoral heterogeneity CD3þ CD8þ Tcell densities microenviron ment DNA mismatchrepairdeﬁcient colon cancers implications prognosis Clin Cancer Res 20192512533 86 Fontana E Eason K Cervantes A et al Context matters consensus molecular subtypes colorectal cancer bio markers clinical trials Ann Oncol 2019305207 87 Lenz HJ Ou FS Venook AP et al Impact consensus molec ular subtype survival patients metastatic colorec tal cancer results CALGBSWOG 80405 alliance JCO 201937187685 88 Aderka D Stintzing S Heinemann V Explaining unex plainable discrepancies results CALGBSWOG 80405 FIRE3 studies Lancet Oncol 201920e27483 89 Becht E Reynies A Giraldo NA et al Immune stromal classiﬁcation colorectal cancer associated molecu lar subtypes relevant precision immunotherapy Clin Cancer Res 201622405766 90 Angelova M Charoentong P Hackl H et al Characterization immunophenotypes antigenomes colorectal cancers reveals distinct tumor escape mechanisms novel targets immunotherapy Genome Biol 20151664 92 Tsantoulis P Hill LA Walker SM et al Association spe ciﬁc innate immune response DNA damage DNA pair deﬁcient colorectal cancers ASCO abstract 3035 J Clin Oncol 2016 93 Viaud S Saccheri F Mignot G et al The intestinal microbiota modulates anticancer immune effects cyclophospha mide Science 20133429716 Iida N Dzutsev A Stewart CA et al Commensal bacteria trol cancer response therapy modulating tumor microenvironment Science 201334296770 94 95 Routy B Le Chatelier E Derosa L et al Gut microbiome inﬂu ences efﬁcacy PD1based immunotherapy epi thelial tumors Science 2018359917 96 Matson V Fessler J Bao R et al The commensal microbiome associated antiPD1 efﬁcacy metastatic mela noma patients Science 20183591048 97 Gopalakrishnan V Spencer CN Nezi L et al Gut microbiome modulates response antiPD1 immunotherapy mela noma patients Science 201835997103 98 Vetizou M Pitt JM Daillere R et al Anticancer immunother apy CTLA4 blockade relies gut microbiota Science 2015350107984 99 Chau I Clinical development PD1PDL1 immunotherapy gastrointestinal cancers facts hopes Clin Cancer Res 201723600211 100 Tesniere A Apetoh L Ghiringhelli F et al Immunogenic cer cell death keylock paradigm Curr Opin Immunol 2008 2050411 101 Antonia SJ Villegas A Daniel D et al Overall survival durvalumab chemoradiotherapy stage III NSCLC N Engl J Med 2018379234250 102 Yi M Qin S Zhao W et al The role neoantigen immune checkpoint blockade therapy Exp Hematol Oncol 2018728 103 Formenti SC Demaria S Radiation therapy convert tumor situ vaccine Int J Radiat Oncol Biol Phys 2012 8487980 104 Whiteside TL Demaria S RodriguezRuiz ME et al Emerging opportunities challenges cancer immunotherapy Clin Cancer Res 201622184555 105 TwymanSaint Victor C Rech AJ Maity A et al Radiation dual checkpoint blockade activate nonredundant immune mechanisms cancer Nature 20155203737 106 Duffy AG MakarovaRusher OV Pratt D et al A pilot study AMP224 PDL2 Fc fusion protein combination ste reotactic body radiation therapy SBRT patients metastatic colorectal cancer ASCO abstract 560 J Clin Oncol 201634560 107 Segal NH Kemeny NE Cercek A et al Nonrandomized phase II study assess efﬁcacy pembrolizumab Pem plus radiotherapy RT ablation mismatch repair proﬁcient pMMR metastatic colorectal cancer mCRC patients ASCO abstract 3539 J Clin Oncol 2016343539 108 Parikh AR Clark JW YonLi Wo J A phase II study ipilimu mab nivolumab radiation microsatellite stable MSS metastatic colorectal adenocarcinoma mCRC ASCO abstract 3514 J Clin Oncol 2019373515 109 Hurwitz H Fehrenbacher L Novotny W et al Bevacizumab plus irinotecan ﬂuorouracil leucovorin metastatic colorectal cancer N Engl J Med 2004350233542 110 Tabernero J Yoshino T Cohn AL et al Ramucirumab versus placebo combination secondline FOLFIRI patients The future immunotherapy pMMRMSS CRC 23 metastatic colorectal carcinoma progressed dur ing ﬁrstline therapy bevacizumab oxaliplatin ﬂuoropyrimidine RAISE randomised doubleblind multicentre phase 3 study Lancet Oncol 201516499508 111 Van Cutsem E Tabernero J Lakomy R et al Addition aﬂi bercept ﬂuorouracil leucovorin irinotecan improves survival phase III randomized trial patients met astatic colorectal cancer previously treated oxaliplatinbased regimen JCO 2012303499506 112 Douillard JY Oliner KS Siena S et al PanitumumabFOLFOX4 treatment RAS mutations colorectal cancer N Engl J Med 2013369102334 113 Van Cutsem E Lenz HJ Kohne CH et al Fluorouracil leuco vorin irinotecan plus cetuximab treatment RAS mutations colorectal cancer JCO 201533692700 114 Kroemer G Galluzzi L Kepp O et al Immunogenic cell death cancer therapy Annu Rev Immunol 2013315172 115 Krysko DV Garg AD Kaczmarek A et al Immunogenic cell death DAMPs cancer therapy Nat Rev Cancer 201212 86075 130 Wallin J Pishvaian MJ Hernandez G et al Clinical activity immune correlates phase Ib study evaluating atezolizumab antiPDL1 combination FOLFOX bevacizumab antiVEGF metastatic colorectal carcinoma AACR abstract 2651 Cancer Res 2016762651 131 Pozzi C Cuomo A Spadoni I et al The EGFRspeciﬁc antibody cetuximab combined chemotherapy triggers immuno genic cell death Nat Med 20162262431 132 Dechant M Weisner W Berger S et al Complementdependent tumor cell lysis triggered combinations epidermal growth factor receptor antibodies Cancer Res 20086849985003 133 Inoue Y Hazama S Suzuki N et al Cetuximab strongly enhances immune cell inﬁltration liver metastatic sites colorectal cancer Cancer Sci 201710845560 134 Stein A Binder M AlBatran SE et al Avelumab cetuximab combination FOLFOX patients cancer previously untreated metastatic MCRC results safety runin phase phase II AVETUX trial AIOKRK0216 ASCO abstract J Clin Oncol 2018363561 colorectal 116 Galluzzi L Buque A Kepp O et al Immunogenic cell death cancer infectious disease Nat Rev Immunol 201717 97111 135 Ebert PJR Cheung J Yang Y et al MAP kinase inhibition pro motes T cell antitumor activity combination PDL1 checkpoint blockade Immunity 20164460921 117 Vincent J Mignot G Chalmin F et al 5Fluorouracil selec tively kills tumorassociated myeloidderived suppressor cells resulting enhanced T celldependent antitumor im munity Cancer Res 201070305261 118 Tanis E Julie C Emile JF et al Prognostic impact immune sponse resectable colorectal liver metastases treated surgery surgery perioperative FOLFOX randomised EORTC study 40983 Eur J Cancer 201551270817 119 Carmeliet P Jain RK Angiogenesis cancer dis eases Nature 200040724957 120 Chen DS Hurwitz H Combinations bevacizumab cancer immunotherapy Cancer J 201824193204 121 Hegde PS Wallin JJ Mancao C Predictive markers anti VEGF emerging role angiogenesis inhibitors immu notherapeutics Semin Cancer Biol 20185211724 122 Villadangos JA Schnorrer P antigenpresenting functions dendriticcell vivo Nat Rev Immunol 2007754355 Intrinsic cooperative subsets 123 Oyama T Ran S Ishida T et al Vascular endothelial growth factor affects dendritic cell maturation inhibi tion nuclear factorkappa B activation hemopoietic progenitor cells J Immunol 1998160122432 124 Jain RK Normalization tumor vasculature emerging concept antiangiogenic therapy Science 20053075862 125 Motz GT Santoro SP Wang LP et al Tumor endothelium FasL establishes selective immune barrier promoting tol erance tumors Nat Med 20142060715 126 Ohm JE Gabrilovich DI Sempowski GD et al VEGF inhibits Tcell development contribute tumorinduced immune suppression Blood 2003101487886 127 Voron T Colussi O Marcheteau E et al VEGFA modulates expression inhibitory checkpoints CD8þ T cells tumors J Exp Med 201521213948 128 Vanneman M Dranoff G Combining immunotherapy targeted therapies cancer treatment Nat Rev Cancer 2012 1223751 129 Bendell JC Powderly JD Lieu CH et al Safety efﬁcacy MPDL3280A antiPDL1 combination bevacizumab bev andor FOLFOX patients pts metastatic colorec tal cancer mCRC ASCO abstract 704 J Clin Oncol 201533 136 Liu L Mayes PA Eastman S et al The BRAF MEK inhibitors dabrafenib trametinib effects immune function combination immunomodulatory antibodies target ing PD1 PDL1 CTLA4 Clin Cancer Res 201521163951 137 Brea EJ Oh CY Manchado E et al Kinase regulation human MHC class I molecule expression cancer cells Cancer Immunol Res 2016493647 138 Eng C Kim TW Bendell J et al Atezolizumab cobimetinib versus regorafenib previously treated meta static colorectal cancer IMblaze370 multicentre open label phase 3 randomised controlled trial Lancet Oncol 20192084961 139 Fruman DA Rommel C PI3K cancer lessons challenges opportunities Nat Rev Drug Discov 20141314056 140 Xue G Zippelius A Wicki A et al Integrated AktPKB signal ing immunomodulation potential role cancer immunotherapy J Natl Cancer Inst 2015 141 Lee S Margolin K Cytokines cancer immunotherapy Cancers Basel 20113385693 142 Steel JC Waldmann TA Morris JC Interleukin15 biology therapeutic implications cancer Trends Pharmacol Sci 2012333541 143 Robinson TO Schluns KS The potential promise IL 15 immunooncogenic therapies Immunol Lett 2017190 15968 144 Zboralski D Hoehlig K Eulberg D et al Increasing tumor inﬁltrating T cells inhibition CXCL12 NOX A12 synergizes PD1 blockade Cancer Immunol Res 2017 59506 145 Hong IS Stimulatory versus suppressive effects GMCSF tumor progression multiple cancer types Exp Mol Med 201648e242 146 van Laar L Coffer PJ Woltman AM Regulation den dritic cell development GMCSF molecular control implications immune homeostasis therapy Blood 2012119338393 147 Mach N Gillessen S Wilson SB et al Differences dendritic cells stimulated vivo tumors engineered secrete granulocytemacrophage colonystimulating factor Flt3 ligand Cancer Res 200060323946 24 N Huyghe et al 148 Qin Z Noffz G Mohaupt M et al Interleukin10 prevents vaccination accumulation dendritic granulocytemacrophage colonystimulating factor gene modiﬁed tumor cells J Immunol 19971597706 cell 149 Gillessen S Naumov YN Nieuwenhuis EE et al CD1d restricted T cells regulate dendritic cell function antitumor immunity granulocytemacrophage colony stimulating factordependent fashion Proc Natl Acad Sci U S A 200310088749 150 Hennequart M Pilotte L Cane S et al Constitutive IDO1 ex pression human tumors driven cyclooxygenase2 mediates intrinsic immune resistance Cancer Immunol Res 20175695709 151 Takikawa O Yoshida R Kido R et al Tryptophan degradation mice initiated indoleamine 2 3dioxygenase J Biol Chem 1986261364853 152 McGaha TL Huang L Lemos H et al Amino acid catabolism innate adaptive immunity pivotal regulator Immunol Rev 201224913557 153 van Baren N Van den Eynde BJ Tumoral immune resistance mediated enzymes degrade tryptophan Cancer Immunol Res 2015397885 154 Ferdinande L Decaestecker C Verset L et al Clinicopathological signiﬁcance indoleamine 2 3dioxygenase 1 expression colorectal cancer Br J Cancer 20121061417 155 Afzal MZ Mercado RR Shirai K Efﬁcacy metformin combination immune checkpoint inhibitors anti PD1antiCTLA4 metastatic malignant melanoma J Immunother Cancer 2018664 156 Palmer TM Trevethick MA Suppression inﬂammatory immune responses A2A adenosine receptor introduction Br J Pharmacol 2008153Suppl 1S2734 157 Zarek PE Huang CT Lutz ER et al A2A receptor signaling promotes peripheral tolerance inducing Tcell anergy generation adaptive regulatory T cells Blood 2008 1112519 158 Schuler PJ Saze Z Hong CS et al Human CD4þ CD39þ regu latory T cells produce adenosine coexpression sur face CD73 contact CD73þ exosomes CD73þ cells Clin Exp Immunol 201417753143 159 Segal NH Saro J Melero I et al Phase I studies novel carcinoembryonic antigen Tcell bispeciﬁc CEACD3 TCB antibody single agent combination atezoli zumab Preliminary efﬁcacy safety patients pts metastatic colorectal cancer mCRC ESMO abstract 403P Ann Oncol 201728Suppl 5v134 160 Gershovich PM Karabelskii AV Ulitin AB et al The role checkpoint inhibitors cytokines adoptive cellbased cancer immunotherapy genetically modiﬁed T cells Biochemistry Moscow 201984695710